IP Library › Granted Patent US 12,517,112
Granted Patent B2
US 12,517,112 · App. 16/954,506 · Granted Jan 6, 2026

Immune cell organoid co-cultures

Inventors: Kai Kretzschmar (Utrecht, NL); Jotam Elazar Bar-Ephraim (Utrecht, NL); Johannes Carolus Clevers (Utrecht, NL); Sylvia Fernandez-Boj (Utrecht, NL); Robert Gerhardus Jacob Vries (Utrecht, NL)
Assignees: Koninklijke Nederlandse Akademie van Wetenschappen; HUB Organoids IP B.V.
G01N33/5011A61K40/11A61K40/32A61K40/4243A61K40/46C12N5/0634C12N5/0693G01N33/5082A61K2239/50C12N2501/2302C12N2501/2307C12N2501/2315C12N2502/11C12N2502/30C12N2503/02C12N2503/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,517,112
App. No.
16/954,506
Granted
Jan 6, 2026
Kind
B2
Abstract

The present invention provides co-cultures of organoids and immune cells, and methods of using these to identify agents for treating diseases.

Claims (81)

1 . A method for identifying an agent suitable for treating a cancer, wherein the method comprises:

contacting a tumouroid co-culture with one or more agents, wherein the tumouroid co-culture comprises immune cells and at least one tumouroid,

detecting the presence or absence of one or more change in the tumouroid co-culture that is indicative of agent suitability for treating the cancer, and

identifying the agent suitable for treating the cancer if the presence or absence of one or more of said changes in the tumouroid co-culture is detected,

wherein the method is preceded by:

preparing the at least one tumouroid by culturing tumour epithelial cells in a tumouroid culture medium;

preparing the immune cells by culturing the immune cells in an immune cell expansion medium, wherein the tumouroid culture medium comprises IL-2 and/or the immune cell expansion medium comprises IL-2; and

preparing the tumouroid co-culture by mixing the at least one tumouroid with the immune cells in an in vitro culture.

2 . The method of claim 1 , wherein the method is preceded by one or more of the following steps:

preparing the immune cells by separating immune cells from an immune sample from a subject; and/or

preparing the tumouroid co-culture by removing the tumouroid culture medium from the at least one tumouroid, and mixing the at least one tumouroid with the immune cells in a tumouroid co-culture medium.

3 . The method of claim 2 , wherein the tumour epithelial cells are obtained from a sample from a cancer patient.

4 . The method of claim 1 , wherein the agent suitable for treating the cancer is identified if the presence or absence of one or more said changes is detected in the tumouroid co-culture but not in a reference organoid co-culture or a reference tumouroid co-culture; and/or

wherein the method is preceded by one or more of the following steps:

preparing at least one organoid by culturing normal epithelial cells in an organoid culture medium; and/or

preparing the immune cells by separating immune cells from an immune sample from a subject, and culturing the immune cells in an immune cell expansion medium; and/or

preparing the reference tumouroid co-culture or the reference organoid co-culture, optionally by removing the tumouroid culture medium or the organoid culture medium from the at least one tumouroid or the at least one organoid, and subsequently mixing the at least one reference organoid or the at least one reference tumouroid with the immune cells in an organoid co-culture medium or a tumouroid co-culture medium,

optionally wherein the immune sample is a tumour sample, normal colon tissue and/or peripheral blood.

5 . The method of claim 4 , wherein the normal epithelial cells are autologous with the tumour epithelial cells.

6 . The method of claim 4 , wherein (i) the tumouroid co-culture medium and/or (ii) the reference organoid co-culture medium or the reference tumouroid co-culture medium, comprises extracellular matrix, optionally selected from collagen, or any animal-derived or synthetic basement membrane matrix, optionally wherein the collagen is rat tail collagen I.

7 . The method of claim 4 , wherein:

(a) the immune cells of the tumouroid co-culture have a motility of at least 40 μm/day; and/or

(b) at least 20% of the immune cells in the tumouroid co-culture moves a distance of at least 200 μm in 80 hours; and/or

(c) the immune cells remain active for at least 4 h; and/or

(d) the one or more agents are of known suitability for treating cancer and the method further comprises identifying the one or more agents as suitable agents for treating cancer in a particular patient.

8 . The method of claim 7 , wherein both the tumouroid co-culture and the reference organoid co-culture or the reference tumouroid co-culture are derived from the particular patient.

9 . The method of claim 4 , wherein the immune cells:

(a) are allogeneic with the tumouroid and/or organoid, optionally wherein the immune cells and tumouroid and/or organoid are derived from either peripheral blood or tissue biopsy of a different patient or healthy control; and/or

(b) are HLA matched with the at least one tumouroid and/or the at least one organoid.

10 . The method of claim 4 , wherein the at least one tumouroid and/or at least one organoid:

(a) comprises or consists of autologous cells; and/or

(b) are separated into populations sharing one or more genotypes.

11 . The method of claim 4 , wherein:

(a) the at least one tumouroid or at least one organoid comprises or consists of mammalian cells or human cells; and/or

(b) the tumouroid co-culture is cultured in (i) immune cell expansion medium or (ii) a 50:50 (v/v) mixture of immune cell expansion medium and tumouroid culture medium; and/or

(c) the organoid co-culture is cultured in (i) immune cell expansion medium or (ii) a 50:50 (v/v) mixture of immune cell expansion medium and organoid culture medium; and/or

(d) the reference organoid co-culture or reference tumouroid co-culture is cultured for at least 4 h.

12 . The method of claim 4 , wherein the tumour epithelial cells or the normal epithelial cells are obtained from a cancer patient; or the tumour epithelial cells and the normal epithelial cells are obtained from different cancer patients; or the tumour epithelial cells and the normal epithelial cells are obtained from a single cancer patient, optionally from the same sample.

13 . The method of claim 1 , wherein the immune cells:

(a) comprise one or more cell types selected from the group consisting of intra-epithelial lymphocytes (IELs), tumour-infiltrating lymphocytes (TILs), peripheral blood mononuclear cells (PBMCs), peripheral blood lymphocytes (PBLs), T cells, and cytotoxic T lymphocytes (CTLs), αβ T cells, γδ T cells, B cells, NK cells, and mononuclear phagocytes; and/or

(b) are obtained from a sample from a cancer patient; and/or

(c) are obtained from a peripheral blood sample and/or a tissue biopsy; and/or

(d) are obtained from the same patient as the tumour epithelial cells; and/or

(e) are allogeneic with the at least one tumouroid, optionally wherein the immune cells and the at least one tumouroid are derived from either peripheral blood or tissue biopsy of a different patient or healthy control; and/or

(f) are HLA matched with the at least one tumouroid; and/or

(g) are cultured in the immune cell expansion medium for at least 4 h.

14 . The method of claim 1 , wherein the at least one tumouroid:

(a) comprises or consists of autologous cells; and/or

(b) are separated into populations sharing one or more genotypes, phenotypes, and/or epigenetic markers, prior to the mixing with immune cells.

15 . The method of claim 1 , wherein:

(a) the at least one tumouroid comprises or consists of mammalian cells or human cells; and/or

(b) the at least one tumouroid co-culture is cultured in immune cell expansion medium or in a 50:50 (v/v) mixture of immune cell expansion medium and tumouroid culture medium; and/or

(c) the tumouroid co-culture is cultured for at least 4 h.

16 . The method of claim 1 , wherein: (a) the tumouroid culture medium comprises IL-2 and the immune cell expansion medium comprises IL 2; and/or (b) the tumouroid co-culture comprises IL-2.

17 . The method of claim 1 , wherein the immune cells are antigenically compatible with a patient from whom the at least one tumouroid is derived.

18 . A method of testing a CAR-T immunotherapy, TCR transgenic T cells, neoantigen, or checkpoint inhibitor, for efficacy and/or safety when used for treating epithelial cancer, the method comprising:

expanding tumour epithelial cells in tumouroid culture medium to form a tumouroid, and mixing the tumouroid with immune cells in a tumouroid co-culture medium comprising an interleukin to form a tumouroid co-culture,

expanding normal epithelial cells in organoid culture medium to form an organoid, and mixing the organoid with immune cells in an organoid co-culture medium comprising the interleukin to form a reference organoid co-culture,

contacting the tumouroid co-culture and reference organoid co-culture with the CAR-T immunotherapy, TCR transgenic T cells, neoantigen, or checkpoint inhibitor,

detecting the presence or absence of one or more change in the tumouroid co-culture and reference organoid co-culture, wherein the presence or absence of one or more change is indicative of efficacy and/or safety of the CAR-T immunotherapy, TCR transgenic T cells, neoantigen, or checkpoint inhibitor, and

comparing the tumouroid co-culture and reference organoid co-culture,

wherein the method is preceded by:

preparing the immune cells by culturing the immune cells in an immune cell expansion medium,

wherein (i) the tumouroid culture medium and/or organoid culture medium comprises IL-2, and/or (ii) the immune cell expansion medium comprises IL-2,

wherein the interleukin is IL-2, IL-7 and/or IL-15.

19 . A method of testing a candidate compound for efficacy and/or safety when used for treating epithelial cancer, the method comprising:

expanding tumour epithelial cells in tumouroid culture medium to form a tumouroid, and mixing the tumouroid with immune cells in a tumouroid co-culture medium comprising an interleukin to form a tumouroid co-culture,

expanding normal epithelial cells in organoid culture medium to form an organoid, and mixing the organoid with immune cells in an organoid co-culture medium comprising the interleukin to form a reference organoid co-culture,

contacting the tumouroid co-culture and reference organoid co-culture with the candidate compound,

detecting the presence or absence of one or more change in the tumouroid co-culture and reference organoid co-culture, wherein the presence or absence of one or more change is indicative of efficacy and/or safety of the candidate compound, and

comparing the tumouroid co-culture and reference organoid co-culture,

wherein the method is preceded by:

preparing the immune cells by culturing the immune cells in an immune cell expansion medium,

wherein (i) the tumouroid culture medium and/or organoid culture medium comprises IL-2, and/or (ii) the immune cell expansion medium comprises IL-2,

wherein the interleukin is IL-2, IL-7 and/or IL-15.

20 . The method of claim 19 , wherein the tumour epithelial cells, the normal epithelial cells, and the immune cells are obtained from a single patient.

21 . A method for testing a therapeutic agent, wherein the method comprises:

contacting an organoid co-culture with one or more agents, wherein the organoid co-culture comprises immune cells and at least one organoid,

detecting the presence or absence of one or more change in the organoid co-culture that is indicative of therapeutic efficacy, and

identifying an agent as a therapeutic agent if the presence or absence of one or more of said changes in the organoid co-culture is detected,

wherein the immune cells and/or the at least one organoid is cultured in the presence of IL-2 prior to formation of the organoid co-culture.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED AT REEL: 66696 FRAME: 917. ASSIGNOR(S) HEREBY CONFIRMS THE DEMERGER. Recorded May 1, 2024
From: STICHTING ONTWIKKELFONDS VOOR ORGANOÏDEN
To: HUB ORGANOIDS IP B.V.
Reel/Frame 067283/0276 →
DEMERGER Recorded Feb 27, 2024
From: STICHTING HUBRECHT ORGANOID BIOBANK
To: STICHTING ONTWIKKELFONDS VOOR ORGANOÏDEN
Reel/Frame 066696/0873 →
DEMERGER Recorded Feb 27, 2024
From: STICHTING ONTWIKKELFONDS VOOR ORGANOÏDEN
To: HUB ORGANOIDS IP B.V.
Reel/Frame 066696/0917 →
CHANGE OF NAME Recorded Feb 26, 2024
From: STICHTING HUBRECHT ORGANOID TECHNOLOGY
To: STICHTING HUBRECHT ORGANOID BIOBANK
Reel/Frame 066556/0404 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2021
From: FERNANDEZ-BOJ, SYLVIA; VRIES, ROBERT GERHARDUS JACOB
To: STICHTING HUBRECHT ORGANOID TECHNOLOGY
Reel/Frame 055925/0833 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2021
From: KRETZSCHMAR, KAI; BAR-EPHRAIM, JOTAM ELAZAR; CLEVERS, JOHANNES CAROLUS
To: KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN
Reel/Frame 056020/0935 →
Priority Claims (1)
GB 1721615 · Dec 21, 2017 · national
Continuity (1)
Related Publication 20210208131A1 · Jul 8, 2021
References Cited (400)
US 5464758A · Gossen et al. · 1995 [cited by applicant]
US 5981483A · Dennis et al. · 1999 [cited by applicant]
US 6165782A · Naldini et al. · 2000 [cited by applicant]
US 6207455B1 · Chang · 2001 [cited by applicant]
US 6218181B1 · Verma et al. · 2001 [cited by applicant]
US 6277633B1 · Olsen · 2001 [cited by applicant]
US 6323031B1 · Cichutek · 2001 [cited by applicant]
US 6432705B1 · Yee et al. · 2002 [cited by applicant]
US 6743626B2 · Baum et al. · 2004 [cited by applicant]
US 7056685B1 · Chen et al. · 2006 [cited by applicant]
US 7411052B2 · Tang · 2008 [cited by applicant]
US 7439927B2 · Lenart et al. · 2008 [cited by applicant]
US 7541431B2 · Yoon · 2009 [cited by applicant]
US 8642339B2 · Sato et al. · 2014 [cited by applicant]
US 8685726B2 · Schulz et al. · 2014 [cited by applicant]
US 8906631B2 · Clevers et al. · 2014 [cited by applicant]
US 9752124B2 · Sato et al. · 2017 [cited by applicant]
US 9765301B2 · Ortega et al. · 2017 [cited by applicant]
US 9833496B2 · Clevers et al. · 2017 [cited by applicant]
US 10006904B2 · Beekman et al. · 2018 [cited by applicant]
US 10597633B2 · Huch Ortega et al. · 2020 [cited by applicant]
US 10940180B2 · Clevers et al. · 2021 [cited by applicant]
US 10947510B2 · Sato et al. · 2021 [cited by applicant]
US 10961511B2 · Sachs et al. · 2021 [cited by applicant]
US 11034935B2 · Huch Ortega et al. · 2021 [cited by applicant]
US 11035852B2 · Beekman et al. · 2021 [cited by applicant]
US 11130943B2 · Sachs et al. · 2021 [cited by applicant]
US 11591572B2 · Clevers et al. · 2023 [cited by applicant]
US 11725184B2 · Ortega et al. · 2023 [cited by applicant]
US 11988661B2 · Beekman et al. · 2024 [cited by applicant]
US 20030003088A1 · Tsao et al. · 2003 [cited by applicant]
US 20030032034A1 · Tang · 2003 [cited by applicant]
US 20030129751A1 · Grikscheit et al. · 2003 [cited by applicant]
US 20030138948A1 · Fisk et al. · 2003 [cited by applicant]
US 20030138951A1 · Yin · 2003 [cited by applicant]
US 20040175367A1 · Herlyn et al. · 2004 [cited by applicant]
US 20040191902A1 · Hambor et al. · 2004 [cited by applicant]
US 20040229355A1 · Chen et al. · 2004 [cited by applicant]
US 20040259177A1 · Lowery et al. · 2004 [cited by applicant]
US 20050054829A1 · Wiley et al. · 2005 [cited by applicant]
US 20050058687A1 · Guarino et al. · 2005 [cited by applicant]
US 20050265980A1 · Chen et al. · 2005 [cited by applicant]
US 20060110369A1 · Funatsu et al. · 2006 [cited by applicant]
US 20060172304A1 · Fuchs et al. · 2006 [cited by applicant]
US 20060182724A1 · Riordan · 2006 [cited by applicant]
US 20070010008A1 · Tseng et al. · 2007 [cited by applicant]
US 20070020637A1 · Isogai et al. · 2007 [cited by applicant]
US 20070036769A9 · Li et al. · 2007 [cited by applicant]
US 20070059829A1 · Yoon · 2007 [cited by applicant]
US 20070122903A1 · Rezania et al. · 2007 [cited by applicant]
US 20070128719A1 · Tseng et al. · 2007 [cited by applicant]
US 20070244061A1 · Niehrs et al. · 2007 [cited by applicant]
US 20070254359A1 · Rezania et al. · 2007 [cited by applicant]
US 20080112890A1 · Lelkes et al. · 2008 [cited by applicant]
US 20080113433A1 · Robins et al. · 2008 [cited by applicant]
US 20080166327A1 · Asahara et al. · 2008 [cited by applicant]
US 20080182328A1 · Snyder et al. · 2008 [cited by applicant]
US 20080233088A1 · Guha et al. · 2008 [cited by applicant]
US 20080242594A1 · Mckay et al. · 2008 [cited by applicant]
US 20090275067A1 · Taniguchi et al. · 2009 [cited by applicant]
US 20090311748A1 · Isogai et al. · 2009 [cited by applicant]
US 20090325289A1 · Hatzfeld · 2009 [cited by applicant]
US 20100047853A1 · Kuo et al. · 2010 [cited by applicant]
US 20100071078A1 · Niehrs · 2010 [cited by applicant]
US 20100112691A1 · Green et al. · 2010 [cited by applicant]
US 20100137210A1 · Funk et al. · 2010 [cited by applicant]
US 20100166713A1 · Dalton et al. · 2010 [cited by applicant]
US 20100247648A1 · Grubb et al. · 2010 [cited by applicant]
US 20100275280A1 · Clevers et al. · 2010 [cited by applicant]
US 20100278800A1 · Boyle et al. · 2010 [cited by applicant]
US 20110002897A1 · Snyder et al. · 2011 [cited by applicant]
US 20110008893A1 · Sugimura et al. · 2011 [cited by applicant]
US 20110191868A1 · Gupta · 2011 [cited by applicant]
US 20120028355A1 · Sato et al. · 2012 [cited by applicant]
US 20120196312A1 · Sato et al. · 2012 [cited by applicant]
US 20120207744A1 · Mendlein et al. · 2012 [cited by applicant]
US 20130005737A1 · Prabhu et al. · 2013 [cited by applicant]
US 20130052729A1 · Pourquie et al. · 2013 [cited by applicant]
US 20130089562A1 · French et al. · 2013 [cited by applicant]
US 20130189327A1 · Ortega et al. · 2013 [cited by applicant]
US 20130280809A1 · Efe et al. · 2013 [cited by applicant]
US 20140044713A1 · De Lau et al. · 2014 [cited by applicant]
US 20140243227A1 · Clevers et al. · 2014 [cited by applicant]
US 20140256037A1 · Sato et al. · 2014 [cited by applicant]
US 20140302491A1 · Nadauld et al. · 2014 [cited by applicant]
US 20150011420A1 · Beekman et al. · 2015 [cited by applicant]
US 20150140013A1 · Ramaswamy · 2015 [cited by applicant]
US 20150231201A1 · Clevers et al. · 2015 [cited by applicant]
US 20150276719A2 · Beekman et al. · 2015 [cited by applicant]
US 20160002595A1 · Keller et al. · 2016 [cited by applicant]
US 20170151308A9 · Clevers et al. · 2017 [cited by applicant]
US 20170191030A1 · Huch Ortega et al. · 2017 [cited by applicant]
US 20170275592A1 · Sachs et al. · 2017 [cited by applicant]
US 20170342385A1 · Sachs et al. · 2017 [cited by applicant]
US 20180025400A1 · Eshun · 2018 [cited by applicant]
US 20180066233A1 · Huch Ortega et al. · 2018 [cited by applicant]
US 20180072995A1 · Sato et al. · 2018 [cited by applicant]
US 20180187191A1 · Zeng · 2018 [cited by applicant]
US 20180221441A1 · Clevers et al. · 2018 [cited by applicant]
US 20180258400A1 · Ng et al. · 2018 [cited by applicant]
US 20190031992A1 · Kerns et al. · 2019 [cited by applicant]
US 20190100728A1 · Sato et al. · 2019 [cited by applicant]
US 20190383799A1 · Beekman et al. · 2019 [cited by applicant]
US 20190390171A1 · Sato et al. · 2019 [cited by applicant]
US 20200172861A1 · Ortega et al. · 2020 [cited by applicant]
US 20200318063A1 · Huch Ortega et al. · 2020 [cited by applicant]
US 20200377860A1 · Freedman et al. · 2020 [cited by applicant]
US 20210040454A1 · Clevers et al. · 2021 [cited by applicant]
US 20210047618A1 · Clevers et al. · 2021 [cited by applicant]
US 20210228682A1 · Clevers et al. · 2021 [cited by applicant]
US 20210254017A1 · Sachs et al. · 2021 [cited by applicant]
US 20210317416A1 · Huch Ortega et al. · 2021 [cited by applicant]
US 20210333266A1 · Beekman et al. · 2021 [cited by applicant]
US 20220017860A1 · Clevers et al. · 2022 [cited by applicant]
US 20220135952A1 · Sachs et al. · 2022 [cited by applicant]
US 20220340879A1 · De Lau et al. · 2022 [cited by applicant]
US 20230272347A1 · Clevers et al. · 2023 [cited by applicant]
US 20240076624A1 · Beumer et al. · 2024 [cited by applicant]
US 20240240155A1 · Pourfarzad et al. · 2024 [cited by applicant]
CN 1596303A · 2005 [cited by applicant]
CN 101240262A · 2008 [cited by applicant]
CN 101420964A · 2009 [cited by applicant]
CN 102439135A · 2012 [cited by applicant]
CN 103180436A · 2013 [cited by applicant]
CN 103237888A · 2013 [cited by applicant]
CN 104508121A · 2015 [cited by applicant]
EA 7611B1 · 2006 [cited by applicant]
EP 0953633A1 · 1999 [cited by applicant]
EP 1347046A1 · 2003 [cited by applicant]
EP 1440981A2 · 2004 [cited by applicant]
EP 1792979A1 · 2007 [cited by applicant]
EP 2138571A1 · 2009 [cited by applicant]
EP 2157192A1 · 2010 [cited by applicant]
EP 1673475B1 · 2010 [cited by applicant]
EP 2228443A1 · 2010 [cited by applicant]
EP 2412800A1 · 2012 [cited by applicant]
EP 2420566A1 · 2012 [cited by applicant]
EP 1427747B1 · 2012 [cited by applicant]
EP 1727560B1 · 2012 [cited by applicant]
EP 2772534A1 · 2015 [cited by applicant]
EP 3143126A1 · 2015 [cited by applicant]
EP 3318627A1 · 2018 [cited by applicant]
EP 3441458A1 · 2019 [cited by applicant]
EP 3505620B1 · 2023 [cited by applicant]
JP 2002247978A · 2002 [cited by applicant]
JP 2006325444A · 2006 [cited by applicant]
JP 2007504823A · 2007 [cited by applicant]
JP 2007116926A · 2007 [cited by applicant]
JP 2008061569A · 2008 [cited by applicant]
JP 2009520474A · 2009 [cited by applicant]
JP 2012000097A · 2012 [cited by applicant]
JP 201651695410999A · 2016 [cited by applicant]
RU 2323252C1 · 2008 [cited by applicant]
RU 2465323C2 · 2012 [cited by applicant]
WO WO9734999A1 · 1997 [cited by applicant]
WO WO0123528A1 · 2001 [cited by applicant]
WO WO01077169A2 · 2001 [cited by applicant]
WO WO0218544A2 · 2002 [cited by applicant]
WO WO03029405A2 · 2003 [cited by applicant]
WO WO03029437A2 · 2003 [cited by applicant]
WO WO03040346A2 · 2003 [cited by applicant]
WO WO03050249A2 · 2003 [cited by applicant]
WO WO03054152A2 · 2003 [cited by applicant]
WO WO03055911A2 · 2003 [cited by applicant]
WO WO2004050827A2 · 2004 [cited by applicant]
WO WO2004076642A2 · 2004 [cited by applicant]
WO WO2004087896A2 · 2004 [cited by applicant]
WO WO2005034625A1 · 2005 [cited by applicant]
WO WO2005040391A1 · 2005 [cited by applicant]
WO WO2005040418A2 · 2005 [cited by applicant]
WO WO2005072419A2 · 2005 [cited by applicant]
WO WO2005110009A2 · 2005 [cited by applicant]
WO WO2005117994A2 · 2005 [cited by applicant]
WO WO2005120547A1 · 2005 [cited by applicant]
WO WO2006104536A2 · 2006 [cited by applicant]
WO WO2007013666A2 · 2007 [cited by applicant]
WO WO2007030290A2 · 2007 [cited by applicant]
WO WO2007050043A2 · 2007 [cited by applicant]
WO WO2007071339A1 · 2007 [cited by applicant]
WO WO2007100357A2 · 2007 [cited by applicant]
WO WO2007127454A2 · 2007 [cited by applicant]
WO WO2007127927A2 · 2007 [cited by applicant]
WO WO2007141657A2 · 2007 [cited by applicant]
WO WO2007149182A2 · 2007 [cited by applicant]
WO WO2008020942A2 · 2008 [cited by applicant]
WO WO2008046649A1 · 2008 [cited by applicant]
WO WO2008075796A1 · 2008 [cited by applicant]
WO WO2008088524A2 · 2008 [cited by applicant]
WO WO2008094597A2 · 2008 [cited by applicant]
WO WO2008101215A1 · 2008 [cited by applicant]
WO WO2008120218A2 · 2008 [cited by applicant]
WO WO2008155120A2 · 2008 [cited by applicant]
WO WO2009005809A2 · 2009 [cited by applicant]
WO WO2009007852A2 · 2009 [cited by applicant]
WO WO2009012428A2 · 2009 [cited by applicant]
WO WO2009022907A2 · 2009 [cited by applicant]
WO WO2009024595A1 · 2009 [cited by applicant]
WO WO2010011352A2 · 2010 [cited by applicant]
WO WO2010015938A2 · 2010 [cited by applicant]
WO WO2010016766A2 · 2010 [cited by applicant]
WO WO2010049752A1 · 2010 [cited by applicant]
WO WO2010077681A1 · 2010 [cited by applicant]
WO WO2010077955A1 · 2010 [cited by applicant]
WO WO2010090513A2 · 2010 [cited by applicant]
WO WO2010108001A2 · 2010 [cited by applicant]
WO WO2010119819A1 · 2010 [cited by applicant]
WO WO2010121923A1 · 2010 [cited by applicant]
WO WO2010129294A3 · 2011 [cited by applicant]
WO WO2011043591A2 · 2011 [cited by applicant]
WO WO2011098402A1 · 2011 [cited by applicant]
WO WO2012014076A2 · 2012 [cited by applicant]
WO WO2012044992A2 · 2012 [cited by applicant]
WO WO2012068251A2 · 2012 [cited by applicant]
WO WO2012087965A2 · 2012 [cited by applicant]
WO WO2012140274A2 · 2012 [cited by applicant]
WO WO2012168930A1 · 2012 [cited by applicant]
WO WO2013054112A1 · 2013 [cited by applicant]
WO WO2013061608A1 · 2013 [cited by applicant]
WO WO2013074681A1 · 2013 [cited by applicant]
WO WO2013093812A2 · 2013 [cited by applicant]
WO WO2014066649A1 · 2014 [cited by applicant]
WO WO2014124527A1 · 2014 [cited by applicant]
WO WO2014127170A1 · 2014 [cited by applicant]
WO WO2014127219A1 · 2014 [cited by applicant]
WO WO2014145389A1 · 2014 [cited by applicant]
WO WO2014159356A1 · 2014 [cited by applicant]
WO WO2014170411A1 · 2014 [cited by applicant]
WO WO2015040142A1 · 2015 [cited by applicant]
WO WO2015173425A1 · 2015 [cited by applicant]
WO WO2015179393A1 · 2015 [cited by applicant]
WO 2015200901A1 · 2015 [cited by applicant]
WO WO2016016894A1 · 2016 [cited by applicant]
WO WO2016056999A1 · 2016 [cited by applicant]
WO WO2016083612A1 · 2016 [cited by applicant]
WO WO2016083613A2 · 2016 [cited by applicant]
WO WO2016094457A1 · 2016 [cited by applicant]
WO WO2017120543A1 · 2017 [cited by applicant]
WO WO2017149025A1 · 2017 [cited by applicant]
WO WO2017205511A1 · 2017 [cited by applicant]
WO WO2017220586A1 · 2017 [cited by applicant]
WO WO2018035138A1 · 2018 [cited by examiner]
WO WO2018052953A1 · 2018 [cited by applicant]
WO WO20180361191A1 · 2018 [cited by applicant]
WO WO2018102102A1 · 2018 [cited by applicant]
WO WO2019122388A1 · 2019 [cited by applicant]
WO WO2019228516A1 · 2019 [cited by applicant]
WO WO2020019023A1 · 2020 [cited by applicant]
WO WO2020205755A1 · 2020 [cited by applicant]
WO WO2020234250A1 · 2020 [cited by applicant]
Gao et al. 3D spheroid/organoid models of lung cancer to study lung cancer pathogenesis and testing of new therapeutics. Journal of Thoracic Oncology, vol. 12, No. 85 (2017) S1544. (Year: 2017). [cited by examiner]
Besser et al., (2009) Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy. Cytotherapy, 11(2), 206-217 (Year: 2009). [cited by examiner]
Neal et al., (2018) Organoid modeling of the tumor immune microenvironment. Cell, 175: 1972-1988 (Year: 2018). [cited by examiner]
Dwyer et al., (2016) A three-dimensional co-culture system to investigate macrophage-dependent tumor cell invasion. J. Biol. Methods, 3(3): e49. (Year: 2016). [cited by examiner]
Nozaki et al. Co-culture with intestinal epithelial organoids allows efficient expansion and motility analysis of intraepithelial lymphocytes. J. Gastroenterol., 51, 206-213 (Year: 2016). [cited by examiner]
Bedke et al., A microplate co-culture assay allows indvidualised compound efficacy testing in patients derived 3D tumour spheroids and autologous immune cells. Euro Urol Suppl Mar. 2017; 16(3): e1474. [cited by applicant]
Chakrabarti et al., Hedgehog signaling regulates PDL-1 expression in gastric cancer cells to induce tumor proliferation (Abstract). Gastroenterology. Su2091. 2 pages. [cited by applicant]
Choo, The HLA system: genetics, immunology, clinical testing, and clinical implications. Yonsei Med J. Feb. 28, 2007;48(1):11-23. [cited by applicant]
Daszkiewicz et al., A 3D image-based quantificaiton of immune cell-tumor spheroid interactions in the presence of checkpoint inhibition. J Clin Oncol. Mar. 2017; 35(7): 82. [cited by applicant]
Daszkiewicz et al., A 3D in vitro culture-based method to visualize and quantify effects of immuno-modulatory drugs. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; Apr. 1-5, 2017; W… [cited by applicant]
Devi et al., Assessing the immunomodulatory role of heteroglycan in a tumor spheroid and macrophage co-culture model system. Carbohydr Polym. 2015;127:1-10. doi: 10.1016/j.carbpol.2015.03.035. Epub Mar. 25, 2015. [cited by applicant]
Finnberg et al., Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures. Oncotarget. Aug. 5, 2017;8(40):66747-66757. [cited by applicant]
Finnberg et al., Use of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures. Cancer Res. 2017; 77(13 Suppl): Abstract Nr 3990. [cited by applicant]
Hirschhaeuser et al., Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action. Cancer Immunol Immunother. Nov. 2010;59(11):1675-84. doi: 10.1007/s00262-010-0894-1. Epub Jul. 21,… [cited by applicant]
Kuball et al., Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood. Mar. 15, 2007;109(6):2331-8. doi: 10.1182/blood-2006-05-023069. Epub Nov. 2, 2006. [cited by applicant]
Nozaki et al., Co-culture with intestinal epithelial organoids allows efficient expansion and motility analysis of intraepithelial lymphocytes. J Gastroenterol. Mar. 2016;51(3):206-13. Epub Jan. 22, 2016. [cited by applicant]
Purwada et al., Modular Immune Organoids with Integrin Ligand Specificity Differentially Regulate Ex Vivo B Cell Activation. ACS Biomater Sci Eng. Feb. 13, 2017;3(2):214-225. doi: 10.1021/acsbiomaterials.6b00474. Epub J… [cited by applicant]
Rabinowitz et al., Transforming growth factor β signaling controls activities of human intestinal CD8(+)T suppressor cells. Gastroenterology. Mar. 2013;144(3):601-612.e1. doi: 10.1053/j.gastro.2012.12.001. Epub Dec. 8, … [cited by applicant]
Rennert et al., A microfluidically perfused three dimensional human liver model. Biomaterials. Dec. 2015;71:119-131. doi: 10.1016/j.biomaterials.2015.08.043. Epub Aug. 25, 2015. [cited by applicant]
Rogoz et al., A 3-D enteroid-based model to study T-cell and epithelial cell interaction. J Immunol Methods. Jun. 2015;421:89-95. doi: 10.1016/j.jim.2015.03.014. Epub Apr. 2, 2015. [cited by applicant]
Sachs et al., Intestinal epithelial organoids fuse to form self-organizing tubes in floating collagen gels. Development. Mar. 15, 2017;144(6):1107-12. [cited by applicant]
Sadelain et al., Therapeutic T cell engineering. Nature. May 24, 2017;545(7655):423-431. [cited by applicant]
Santhanam et al., Upregulated pathways and products of tryptophan metabolism is associated with the neoplastic transition in the colon epithelium. AGA Abstracts. Su1195. 1 page. [cited by applicant]
Schumacher et al., The use of murine-derived fundic organoids in studies of gastric physiology. J Physiol. Apr. 15, 2015;593(8):1809-27. doi: 10.1113/jphysiol.2014.283028. Epub Feb. 19, 2015. [cited by applicant]
Sebestyen et al., RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell Receptor. Cell Rep. May 31, 2016;15(9):1973-85. doi: 10.1016/j.celrep.2016.04.081. Epub May 19, 2016. [cited by applicant]
Shiina et al., MHC genotyping in human and nonhuman species by PCR-based next-generation sequencing. Next Generation Sequencing—Advances, Applications and Challenges:Chapter 3. 2015. [cited by applicant]
Tian et al., Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells. Biomaterials. Dec. 2015;73:110-9. doi: 10.1016/j.biomaterials.2015.09.007. Epub Sep. 11, 2015. [cited by applicant]
Upton et al., De novo synthesis of T cells from mPB CD34+ cells cultured in a 3-dimensional thymic organoid. Blood. 2003; 102(11): 279a. [cited by applicant]
U.S. Appl. No. 60/339,739, filed Dec. 10, 2001, Tang et al. [cited by applicant]
JP Notice of Reasons for Rejection mailed Sep. 3, 2012, for Application No. JP2011- 547839. [cited by applicant]
JP Notice of Reasons for Rejection mailed Oct. 3, 2013, for Application No. JP2012-158676. [cited by applicant]
JP Notice of Reasons for Rejection mailed Sep. 7, 2015, for Application No. JP2013- 521247. [cited by applicant]
International Search Report and Written Opinion dated Jun. 3, 2019, for Application No. PCT/EP2018/086716. [cited by applicant]
International Preliminary Report on Patentability dated Jul. 2, 2020, for Application No. PCT/EP2018/086716. [cited by applicant]
“The Wnt Family of Secreted Proteins”, R&D Systems' 2004 Catalog, 7 pages (Jan. 1, 2004). [cited by applicant]
[No Author Listed] “Art Levinson, Sergey Brin and Anne Wojcicki, Mark Zuckerberg and Priscilla Chan, and Yuri Milner Announce the Breakthrough Prize in Life Sciences”, Breakthrough Prize. Feb. 20, 2013: 3pgs. https://br… [cited by applicant]
[No Author Listed] An open label dose-escalation study of a self-complementary adeno-associated viral vector (scAAV2/8-LP1-hFIXco) for gene transfer in hemophilia B. ClinicalTrials.gov Archive. Jun. 29, 2010. Identifier… [cited by applicant]
[No Author Listed] Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. Jan. 29, 2015;517(7536):576-82. doi: 10.1038/nature14129. [cited by applicant]
[No Author Listed] Definition of “Organoid”, MediLexicon Dictionary. 2006, p. 1. http://www.medilexicon.com/medicaldictionary.php?t=63274. [cited by applicant]
[No Author Listed] G.I Research. 2004;12(2):3-10. Japanese. [cited by applicant]
[No Author Listed] Gastroenterology. 2005;128(4):Suppl. 2, A702. Abstract S1225. [cited by applicant]
[No Author Listed] Ministry of Health, Labour and Welfare, Ethical guidelines for clinical studies. Dated Jul. 30, 2003: p. 3. Accessed from <http://www.mhlw.go.jp/general/seido/kousei/i-kenkyu/rinsyo/dl/shishin.pdf.> J… [cited by applicant]
[No Author Listed] Notch Signaling Pathway. Retrieved from the internet <https://www.sinobiological.com/pathways/notch-pathway> Nov. 5, 2020. 3 pages. [cited by applicant]
[No Author Listed] Purified Human Pancreatic Islets, In Vivo Islets Function. Document No. 3104, A04, Effective Date Jul. 7, 2008. DAIT, NIAID, NIH. [cited by applicant]
[No Author Listed] TGF-beta Inhibitor. Retrieved from the internet <https://kr.sinobiological.com/resource/cytokines/tgf-beta-inhibitors> Nov. 5, 2020. 6 pages. [cited by applicant]
[No Author Listed] TGF-beta Signaling Pathway. Retrieved from the internet <https://www.sinobiological.com/pathways/tgf-beta-pathway> Nov. 5, 2020. 3 pages. [cited by applicant]
[No Author Listed] The Wnt family of secreted proteins. R&D Systems. Jan. 1, 2004. http://www.rndsystems.com/mini_review_detail_objectname_MR04_WntFamily.aspx. 7 pages. [cited by applicant]
Abe et al., Apoptosis of mouse pancreatic acinar cells after duct ligation. Arch Histol Cytol. Jun. 1995;58(2):221-9. [cited by applicant]
Abud et al., Growth of intestinal epithelium in organ culture is dependent on EGF signalling. Exp Cell Res. Feb. 15, 2005;303(2):252-62. [cited by applicant]
Afroze et al., “The physiological roles of secretin and its receptor.” Ann Transl Med. Oct. 2013; 1(3):29. doi: 10.3978/j.issn.2305-5839.2012.12.01. [cited by applicant]
Ahmed et al., Extracellular Matrix Regulation of Stem Cell Behavior. Curr Stem Cell Rep. 2016;2(3):197-206. doi: 10.1007/s40778-016-0056-2. Epub Jul. 7, 2016. [cited by applicant]
Aini et al. Accelerated telomere reduction and hepatocyte senescence in tolerated human liver allografts. Transpl Immunol. Aug. 2014;31(2):55-9. doi: 10.1016/j.trim.2014.06.008. Epub Jun. 30, 2014. [cited by applicant]
Al-Lazikani et al., Standard conformations for the canonical structures of immunoglobulins. J Mol Biol. Nov. 7, 1997;273(4):927-48. doi: 10.1006/jmbi.1997.1354. [cited by applicant]
Amado et al., Lentiviral vectors—the promise of gene therapy within reach? Science. Jul. 30, 1999;285(5428):674-6. [cited by applicant]
Anders et al., Differential expression analysis for sequence count data. Genome Biol. 2010; 11(10):R106. doi: 10.1186/GB-2010-11-10-r106. Epub Oct. 27, 2010. [cited by applicant]
Anderson, Human gene therapy. Nature. Apr. 30, 1998;392(6679 Suppl):25-30. [cited by applicant]
Andersson et al., Pharmacokinetics of cisplatin and its monohydrated complex in humans. J Pharm Sci. Aug. 1996;85(8):824-7. doi: 10.1021/js960037a. [cited by applicant]
Apelqvist et al., Notch signalling controls pancreatic cell differentiation. Nature. Aug. 26, 1999;400(6747):877-81. [cited by applicant]
Apte et al., Wnt/beta-catenin signaling mediates oval cell response in rodents. Hepatology. Jan. 2008;47(1):288-95. [cited by applicant]
Argiris et al., Head and neck cancer. Lancet. May 17, 2008;371(9625):1695-709. doi: 10.1016/S0140-6736(08)60728-X. Author Manuscript, 32 pages. [cited by applicant]
Azuma et al., Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/I12rg-/- mice. Nat Biotechnol. Aug. 2007;25(8):903-10. Epub Jul. 29, 2007. Author manuscript available in PMC Jul. 25, 2012. [cited by applicant]
Bainbridge et al., Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. May 22, 2008;358(21):2231-9. doi: 10.1056/NEJMoa0802268. Epub Apr. 27, 2008. [cited by applicant]
Bakkebø et al., TGF-β-induced growth inhibition in B-cell lymphoma correlates with Smad1/5 signalling and constitutively active p38 MAPK. BMC Immunol. Nov. 23, 2010;11:57. doi: 10.1186/1471-2172-11-57. [cited by applicant]
Barker et al., Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature. Oct. 25, 2007;449(7165):1003-7. Epub Oct. 14, 2007. [cited by applicant]
Barker et al., Lgr proteins in epithelial stem cell biology. Development. Jun. 2013;140(12):2484-94. [cited by applicant]
Barker et al., Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell. Jan. 8, 2010;6(1):25-36. [cited by applicant]
Barker et al., The intestinal stem cell. Genes Dev. Jul. 15, 2008;22(14):1856-64. [cited by applicant]
Barker et al., Tissue-resident adult stem cell populations of rapidly self-renewing organs. Cell Stem Cell. Dec. 3, 2010;7(6):656-70. [cited by applicant]
Barrentina et al., The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. Mar. 28, 2012;483(7391):603-7. doi: 10.1038/nature11003. Erratum in: Nature. Dec. 13, 2012;492(74… [cited by applicant]
Bartfeld et al., In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection. Gastroenterology. Jan. 2015;148(1):126-136.e6. doi: 10.1053/j.gastro.2014.09.042. Epub Oct. 13, 2014. [cited by applicant]
Batlle et al., Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell. Oct. 18, 2002;111(2):251-63. [cited by applicant]
Bhosale et al., Chromosomal Alterations and Gene Expression Changes Associated with the Progression of Leukoplakia to Advanced Gingivobuccal Cancer. Transl Oncol. Jun. 2017;10(3):396-409. doi: 10.1016/j.tranon.2017.03.0… [cited by applicant]
Bigorgne et al., TTC7A mutations disrupt intestinal epithelial apicobasal polarity. J Clin Invest. Jan. 2014;124(1):328-37. doi: 10.1172/JCI71471. [cited by applicant]
Billerbeck et al., Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells. J Hepatol. Aug. 2016;65(2):334-43. doi: 10.1016/j.jhep.2016.04.022. Epub M… [cited by applicant]
Binnerts et al., R-Spondin1 regulates Wnt signaling by inhibiting internalization of LRP6. Proc Natl Acad Sci U S A. Sep. 11, 2007;104(37):14700-5. Epub Sep. 2007. [cited by applicant]
Bjerknes et al., Clonal analysis of mouse intestinal epithelial progenitors. Gastroenterology. Jan. 1999;116(1):7-14. [cited by applicant]
Bjerknes et al., Intestinal epithelial stem cells and progenitors. Methods Enzymol. 2006;419:337-83. [cited by applicant]
Bjerknes et al., Multipotential stem cells in adult mouse gastric epithelium. Am J Physiol Gastrointest Liver Physiol. Sep. 2002;283(3):G767-77. [cited by applicant]
Blanpain et al., Epithelial stem cells: turning over new leaves. Cell. Feb. 9, 2007;128(3):445-58. [cited by applicant]
Bodnar et al., Characterization of human islet-like structures generated from pancreatic precursor cells in culture. Biotechnol Bioeng. Apr. 5, 2006;93(5):980-8. [cited by applicant]
Boj et al., Organoid models of human and mouse ductal pancreatic cancer. Cell. Jan. 15, 2015;160(1-2):324-38. doi: 10.1016/j.cell.2014.12.021. Epub Dec. 31, 2014. [cited by applicant]
Bonaguidi et al., LIF and BMP signaling generate separate and discrete types of GFAP-expressing cells. Development. Dec. 2005;132(24):5503-14. [cited by applicant]
Bonaguidi et al., Noggin expands neural stem cells in the adult hippocampus. J Neurosci. Sep. 10, 2008;28(37):9194-204. doi: 10.1523/JNEUROSCI.3314-07.2008. [cited by applicant]
Bonner-Weir et al., In vitro cultivation of human islets from expanded ductal tissue. Proc Natl Acad Sci U S A. Jul. 5, 2000;97(14):7999-8004. [cited by applicant]
Bonner-Weir et al., New sources of pancreatic beta-cells. Nat Biotechnol. Jul. 2005;23(7):857-61. [cited by applicant]
Booth et al., Maintenance of functional stem cells in isolated and cultured adult intestinal epithelium. Exp Cell Res. Jun. 15, 1999;249(2):359-66. [cited by applicant]
Booth et al., The isolation and culture of adultmouse colonic epithelium. Epithelial Cell Biol. 1995;4(2):76-86. [cited by applicant]
Bossi et al., Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. Oncotarget. Nov. 8, 2016;7(45):74362-74379. doi: 10.18632/oncotarget.11413. [cited by applicant]
Bottenstein et al., Growth of a rat neuroblastoma cell line in serum-free supplemented medium. Proc Natl Acad Sci U S A. Jan. 1979;76(1):514-7. [cited by applicant]
Bottenstein et al., Growth of a rat neuroblastoma cell line in serum-free supplemented medium. Proc Natl Acad Sci U S A. Jan. 1979;76(1):514-7. doi: 10.1073/pnas.76.1.514. [cited by applicant]
Boutten et al., Oncostatin M is a potent stimulator of alpha1-antitrypsin secretion in lung epithelial cells: modulation by transforming growth factor-beta and interferon-gamma. Am J Respir Cell Mol Biol. Apr. 1998;18(4… [cited by applicant]
Bouwens et al., Regulation of pancreatic beta-cell mass. Physiol Rev. Oct. 2005;85(4):1255-70. [cited by applicant]
Braakhuis et al., The potential of the nude mouse xenograft model for the study of head and neck cancer. Arch Otorhinolaryngol. 1984;239(1):69-79. doi: 10.1007/BF00454264. [cited by applicant]
Brassard et al., Engineering Stem Cell Self-organization to Build Better Organoids. Cell Stem Cell. Jun. 6, 2019;24(6):860-876. doi: 10.1016/j.stem.2019.05.005. [cited by applicant]
Brewer et al., Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurosci Res. Aug. 1, 1993;35(5):567-76. [cited by applicant]
Brinster et al., Regulation of metallothionein--thymidine kinase fusion plasmids injected into mouse eggs. Nature. Mar. 4, 1982;296(5852):39-42. [cited by applicant]
Brockbank et al., Cryopreservation Guide. 2007. Retrieved from the Internet: https://www.thermofisher.co.nz/Uploads/file/Scientific/Applications/Equipment-Furniture/Cryopreservation-Guide.pdf on May 2, 2019. 30 pages. [cited by applicant]
Broutier et al., Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat Protoc. Sep. 2016;11(9):1724-43. doi: 10.1038/nprot.2016.097. Epub Au… [cited by applicant]
Broutier et al., Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med. Dec. 2017;23(12):1424-1435. doi: 10.1038/nm.4438. Epub Nov. 13, 2017. [cited by applicant]
Buczacki et al., Intestinal label-retaining cells are secretory precursors expressing Lgr5. Nature. Mar. 7, 2013; 495(7439):65-9. doi: 10.1038/nature11965. Epub Feb. 27, 2013. [cited by applicant]
Burke et al., Liver zonation occurs through a beta-catenin-dependent, c-Myc-independent mechanism. Gastroenterology. Jun. 2009;136(7):2316-2324.e1-3. doi: 10.1053/j.gastro.2009.02.063. Epub Mar. 5, 2009. [cited by applicant]
Buset et al., Defining conditions to promote the attachment of adult human colonic epithelial cells. In Vitro Cell Dev Biol. Jun. 1987;23(6):403-12. [cited by applicant]
Byron et al., Anti-integrin monoclonal antibodies. J Cell Sci. Nov. 15, 2009;122(Pt 22):4009-11. doi: 10.1242/jcs.056770. [cited by applicant]
Cai et al., Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma. Oncotarget. Mar. 28, 2017;8(13):22203-22217. doi: 10.18632/oncotarget.14729. [cited by applicant]
Calderwood DA. Integrin activation. J Cell Sci. Feb. 15, 2004;117(Pt 5):657-66. doi: 10.1242/jcs.01014. [cited by applicant]
Capaccio et al., Modern management of obstructive salivary diseases. Acta Otorhinolaryngol Ital. Aug. 2007;27(4):161-72. [cited by applicant]
Caplen et al., Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci U S A. Aug. 14, 2001;98(17):9742-7. Epub Jul. 31, 2001. [cited by applicant]
Carraway et al., Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. Nature. May 29, 1997; 387(6632):512-6. [cited by applicant]
Cassiman et al. The vagal nerve stimulates activation of the hepatic progenitor cell compartment via muscarinic acetylcholine receptor type 3. Am J Pathol. Aug. 2002;161(2):521-30. [cited by applicant]
Castillo-Gonzalez et al., Dysregulated cholinergic network as a novel biomarker of poor prognostic in patients with head and neck squamous cell carcinoma. BMC Cancer. May 10, 2015;15:385. doi: 10.1186/s12885-015-1402-y. [cited by applicant]
Cavalieri et al., Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. Eur J Cancer. Jul. 2… [cited by applicant]
Chai et al., Wnt signaling induces proliferation of sensory precursors in the postnatal mouse cochlea. Proc Natl Acad Sci U S A. May 22, 2012;109(21):8167-72. doi: 10.1073/pnas.1202774109. Epub May 4, 2012. [cited by applicant]
Chapman et al., Analysis of spatial and temporal gene expression patterns in blastula and gastrula stage chick embryos. Dev Biol. May 1, 2002;245(1):187-99. [cited by applicant]
Chatterjee et al., Induced Pluripotent Stem (IPS) Cell Culture Methods and Induction of Differentiation into Endothelial Cells. Methods Mol Biol. 2016;1357:311-27. [cited by applicant]
Chen et al., Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol. Feb. 2009;5(2):100-7. Epub Jan. 4, 2009. [cited by applicant]
Cheng et al., Central and peripheral administration of secretin inhibits food intake in mice through the activation of the melanocortin system. Neuropsychopharmacology. Jan. 2011; 36(2):459-71. doi: 10.1038/npp.2010.178… [cited by applicant]
Cheng et al., Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine. I. Columnar cell. Am J Anat. Dec. 1974;141(4):461-79. [cited by applicant]
Chun et al., A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res. Nov. 15, 2001;61(22):8164-70. Erratum in: Cancer Res Feb. 15, 2002;62(4):1232. [cited by applicant]
Clarke et al., Cancer stem cells—perspectives on current status and future directions: AACR Workshop on Cancer Stem Cells. Cancer Res. 2006;66:9339-44. [cited by applicant]
Clarkson et al., Oral Viral Infections: Diagnosis and Management. Dent Clin North Am. Apr. 2017;61(2):351-363. doi: 10.1016/j.cden.2016.12.005. [cited by applicant]
Clevers et al. Cell Technology. 2009; 28(7):702-03. Japanese. [cited by applicant]
Clevers, Modeling Development and Disease with Organoids. Cell. Jun. 16, 2016;165(7):1586-1597. doi: 10.1016/j.cell.2016.05.082. [cited by applicant]
Clotman et al., Control of liver cell fate decision by a gradient of TGFβ signaling modulated by Onecut transcription factors. Genes & Dev. 2005; 19:1849-54. [cited by applicant]
Co et al., Controlling Epithelial Polarity: A Human Enteroid Model for Host-Pathogen Interactions. Cell Rep. Feb. 26, 2019;26(9):2509-2520.e4. doi: 10.1016/j.celrep.2019.01.108. [cited by applicant]
Cole et al., Measuring GSK3 expression and activity in cells. Methods Mol Biol. 2008; 468:45-65. doi: 10.1007/978-1-59745-249-6_4. [cited by applicant]
Corro et al., A brief history of organoids. Am J Physiol Cell Physiol. Jul. 1, 2020;319(1):C151-C165. doi: 10.1152/ajpcell.00120.2020. Epub May 27, 2020. [cited by applicant]
Couchie et al., In vitro differentiation of WB-F344 rat liver epithelial cells into the biliary lineage. Differentiation. Jan. 2002;69(4-5):209-15. doi: 10.1046/j.1432-0436.2002.690414.x. [cited by applicant]
Crawford et al., The notch response inhibitor DAPT enhances neuronal differentiation in embryonic stem cell-derived embryoid bodies independently of sonic hedgehog signaling. Dev Dyn. Mar. 2007;236(3):886-92. [cited by applicant]
Crosnier et al., Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. Nat Rev Genet. May 2006;7(5):349-59. [cited by applicant]
Cruz-Acuna et al., Synthetic hydrogels for human intestinal organoid generation and colonic wound repair. Nat Cell Biol. Nov. 2017;19(11):1326-1335. doi: 10.1038/ncb3632. Epub Oct. 23, 2017. [cited by applicant]
Cuny et al., Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett. Aug. 1, 2008; 18(15):4388-92. doi: 10.1016/j.bmcl.2008.06.052. Epub Jun. 27, 2008. [cited by applicant]
De Gouville et al., Inhibition of TGF-β signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br J Pharmacol. May 2005;145(2):166-77. [cited by applicant]
De La Costa et al., Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A. Jul. 21, 1998;95(15):8847-51. doi: 10.1073/pnas.95.15.8847. [cited by applicant]
De Lau et al., Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature. Jul. 4, 2011;476(7360):293-7. doi: 10.1038/nature10337. [cited by applicant]
De Lau et al., The R-spondin protein family. Genome Biol. 2012;13(3):242. doi: 10.1186/gb-2012-13-3-242. [cited by applicant]
De Lau et al., The R-spondin/Lgr5/Rnf43 module: regulator of Wnt signal strength. Genes Dev. Feb. 15, 2014;28(4):305-16. doi: 10.1101/gad.235473.113. [cited by applicant]
Dekkers et al., A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med. Jul. 2013; 19(7):939-45. doi: 10.1038/nm.3201. Epub Jun. 2, 2013. [cited by applicant]
Denu, Vitamin B3 and sirtuin function. Trends Biochem Sci. Sep. 2005;30(9):479-83. [cited by applicant]
Deveney et al., Establishment of human colonic epithelial cells in long-term culture. J Surg Res. Aug. 1996;64(2):161-9. [cited by applicant]
Dey et al., Phenotypic and functional characterization of human mammary stem/progenitor cells in long term culture. PLoS One. 2009;4(4):e5329. doi: 10.1371/journal.pone.0005329. Epub Apr. 24, 2009. [cited by applicant]
Dignass et al., Peptide growth factors in the intestine. Eur J Gastroenterol Hepatol. Jul. 2001;13(7):763-70. [cited by applicant]
Dijkstra et al., Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. Cell. Sep. 6, 2018;174(6):1586-1598.e12. doi: 10.1016/j.cell.2018.07.009. Epub Aug. 9, 2018. [cited by applicant]
Dollé et al., EpCAM and the biology of hepatic stem/progenitor cells. Am J Physiol Gastrointest Liver Physiol. Feb. 1, 20155;308(4):G233-50. doi: 10.1152/ajpgi.00069.2014. Epub Dec. 4, 2014. [cited by applicant]
Dong et al., The epithelial-mesenchymal transition promotes transdifferentiation of subcutaneously implanted hepatic oval cells into mesenchymal tumor tissue. Stem Cells Dev. Nov. 2009;18(9):1293-8. doi: 10.1089/scd.200… [cited by applicant]
Dontu et al., Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004; 6(6):R605-15. Epub Aug. 1, 20046. [cited by applicant]
Dor et al., Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature. May 6, 2004;429(6987):41-6. [cited by applicant]
Dorrell et al., Surface markers for the murine oval cell response. Hepatology. Oct. 2008; 48(4):1282-91. doi: 10.1002/hep.22468. [cited by applicant]
Dou et al., Expanding Sca-1(+) mammary stem cell in the presence of oestrogen and growth hormone. Clin Transl Oncol. Jun. 2012; 14(6):444-51. doi: 10.1007/s12094-012-0822-2. [cited by applicant]
Drew et al., Comparison of 2 cell-based phosphoprotein assays to support screening and development of an ALK inhibitor. J Biomol Screen. Feb. 2011;16(2):164-73. doi: 10.1177/1087057110394657. [cited by applicant]
Driehuis et al., Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy. Cancer Discov. Jul. 2019;9(7):852-871. doi: 10.1158/2159-8290.CD-18-1522. Epub May 3, 2019. Erratum in: Cancer Discov. Mar… [cited by applicant]
Driehuis et al., WNT signalling events near the cell membrane and their pharmacological targeting for the treatment of cancer. Br J Pharmacol. Dec. 2017; 174(24):4547-4563. doi: 10.1111/bph.13758. Epub Apr. 4, 2017. [cited by applicant]